a Department of Ophthalmology and Ophtha Lab at St. Franziskus-Hospital Münster , Münster , Germany.
b Department of Pediatric Rheumatology and Immunology , University Hospital Münster , Münster , Germany.
Ocul Immunol Inflamm. 2019;27(2):330-337. doi: 10.1080/09273948.2017.1374415. Epub 2017 Oct 11.
This study analyzed the effect of adalimumab on peripheral blood mononuclear cells (PBMCs) in uveitis.
PBMCs and serum S100A12 levels from 14 uveitis patients and 28 healthy controls were analyzed. Patient samples were taken before (w0), and 6 (w6) and 12 (w12) weeks after initiation of adalimumab therapy.
Monocytes expressing CD124, CD86, CD39, CD115, and MHCII were decreased in patients. Adalimumab induced CD86+ and CD39+ monocytes, and further decreased the frequency of MHCII- and CD124-positive cells. Patients (w0) had increased percentages of Th1-, Th17-, and Th2 cells and T cell subsets showed a pro-inflammatory polarization (p = 0.02 ratio Th17/Treg patients w0 vs controls), which was reduced upon adalimumab treatment (p = 0.05 w0 vs w6). S100A12 levels were increased in patients (p = 0.02) and reduced under treatment (p = 0.02 for w6/w12).
The phenotype of PBMCs from uveitis patients is modified upon adalimumab treatment. Serum S100A12 levels reflect the systemic immune response.
本研究分析了阿达木单抗对葡萄膜炎患者外周血单个核细胞（PBMC）的影响。
分析了 14 例葡萄膜炎患者和 28 名健康对照者的 PBMC 和血清 S100A12 水平。患者样本分别在起始阿达木单抗治疗前（w0）、6 周（w6）和 12 周（w12）时采集。
患者单核细胞表达 CD124、CD86、CD39、CD115 和 MHCII 的比例降低。阿达木单抗诱导 CD86+和 CD39+单核细胞，并进一步降低 MHCII-和 CD124 阳性细胞的频率。患者（w0）中 Th1、Th17 和 Th2 细胞的比例增加，T 细胞亚群表现出促炎极化（p=0.02 比值 Th17/Treg 患者 w0 与对照），经阿达木单抗治疗后减少（p=0.05 w0 与 w6）。S100A12 水平在患者中升高（p=0.02），治疗后降低（p=0.02 为 w6/w12）。
阿达木单抗治疗后葡萄膜炎患者 PBMC 的表型发生改变。血清 S100A12 水平反映了全身免疫反应。
